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Abstract 
Introduction: Little is written about the rehabilitation of those with rare diseases and their use 
of powered wheelchairs. 
Purpose: The aim of this study is to describe the clinical features of electric powered 
indoor/outdoor wheelchairs (EPIOC) users with rare diseases (RD) that impact on EPIOC 
provision and seating needs. 
Method: Retrospective review of electronic and case note records of EPIOC recipients 
attending a specialist wheelchair service between June 2007 and September 2008. 
Records were reviewed by a consultant in rehabilitation medicine, data systematically 
extracted and entered into a computer database. Further data were entered from clinical 
records and extracted under three themes; demographic, diagnostic, clinical (including 
comorbidity and associated features of the illness/disability (ACFs)) and wheelchair factors. 
Records were reviewed a mean of 64 (range 0-131) months after receiving their wheelchair. 
Results: Fifty four (27 male) EPIOC users, mean age 37.3 (sd 18.6, range 11-70) met the 
inclusion criteria. Diagnoses included Friedreich’s ataxia (n=10), motorneurone disease 
(n=6), osteogenesis imperfecta (n=4), arthrogryposis (n=4), cerebellar syndromes (n=4) and 
others (n=26). Nineteen users had between them 36 comorbidities and 30 users had 44 ACFs 
likely to influence the prescription. Tilt-in-space was provided to 34 (63%) users and 
specialised seating to 17 (31%). Those provided with SS were significantly younger than 
those who had standard equipment (p<0.004). Four users had between them complex control 
or interfacing issues. Two users required support for oxygen cylinders. 
Conclusions: This study contributes to the limited understanding of the rehabilitation needs of 
severely mobility impaired individuals with rare diseases from the perspective of a powered 
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wheelchair service. Rehabilitation is complicated by comorbidity and the complex clinical 
findings in this group of wheelchair users. 
Key words: comorbidity, Friedreich’s ataxia, rare diseases, rehabilitation, wheelchairs  
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Rare diseases (RD) are conditions affecting less than five in 10,000 of the general 
population
1
, or a prevalence of fewer than 200,000 affected individuals in the USA
2
. Many 
are life-threatening or chronically debilitating diseases, often of genetic origin
1
. Whilst the 
diagnosis and medical management of RD have advanced, little is published on the functional 
impact on individuals with these disorders experiencing progressive disabilities. 
It has been recommended that more research is needed into management of patients with RD 
to underpin the development of guidelines to improve care
3
.  
For those severely affected by RD, mobility disability has an impact on activities, 
participation and quality of life (QoL). The consideration of wheeled and/or powered 
mobility can provide substantial improvements to QOL 
4
. The limited literature on 
rehabilitation and RD, and the even rarer literature on wheelchair use, appears negative in 
nature – in that a condition had deteriorated such that a wheelchair was needed for mobility5-
9
. UK Reports make no reference to mobility disability and the need for a full disability 
assessment and rehabilitation
3
. This is surprising in view of the proven benefits of powered 
mobility to the wellbeing of EPIOC users (referred to as ‘users’), particularly the 
psychological gains experienced by younger users
10
. However the value of assistive 
technologies for those with RD and their families is understood and promoted in the USA
11
. 
Previous research has identified the wide range of diagnoses, age and associated clinical 
features of recipients of EPIOCs. This research commented on the complex interactions 
between the chair user and the technical features of EPIOC prescription
12
. We explored a 
subgroup of this study population with severe mobility disability diagnosed with RDs that 
were of metabolic, neuromuscular or neurological origin.  
The aim of this study is to describe those clinical features of EPIOC users with RD that 
impact on EPIOC provision and seating needs.  
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Methods 
The setting 
The Specialist Wheelchair Service at Stanmore was set up in 1997 
13
 to provide a regional 
service for around 3.1 million people from both rural and inner city areas. Provision was 
limited to those who were unable to walk safely around their home, unable to self-propel and 
were judged safe to use their chairs in public places irrespective of age, diagnosis or time 
using a wheelchair (if any)
13
.  
Provision involved: -  
1. Completion of a screening questionnaire. 
2. Occupational therapy assessment for the suitability of the home environment and the 
likelihood that the eligibility criteria would be fulfilled. 
3. Assessment at the specialist regional service including eye and physical examination 
to define any problems with seating or controlling a powered wheelchair, concluding 
with a driving assessment to ensure satisfactory control of the wheelchair and safety 
for the users and others.  
4. A rehabilitation engineer delivered the wheelchair and explained its use, checked 
seating and that driving appeared satisfactory. 
Participants 
Potential participants lived in the community and were referred from their local wheelchair 
service to the regional service. All individuals who had been prescribed an EPIOC and were 
currently using their chair were of interest to this study. Users relevant to this research had a 
diagnosis of a rare disease defined as conditions affecting less than five in 10,000 of the 
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general population
1
, of metabolic, neurological or neuromuscular origin, and recorded as the 
main diagnosis for ten or fewer individuals. Data had been recorded by health professionals 
after physical examination. Assessment included demographic data, clinical issues and 
wheelchair factors. Data were entered into electronic records and were reviewed between 
June 2007 and September 2008 by a consultant physician in rehabilitation medicine.  Data 
were systematically extracted and entered into a computer database for analysis. Further data 
were entered from the clinical notes (charts) and all data anonymised.  
Data relating to demographic profile, clinical profile and wheelchair factors were extracted 
for analysis. Demographic profiles consisted of information on age at initial assessment and 
gender. Clinical profiles included: primary diagnosis, comorbidities, other clinical features 
and complications relating to the disability.  
Wheelchair factors included information about specialised seating (SS)(adaptive seating), 
defined as ‘that which is needed by people who require a wheelchair but due to instability or 
deformity need additional support in order to function’14. Other data included tilt-in-space 
(TIS), cushions and complex controls. 
Methods of analysis 
This was a sub-group analysis of EPIOC users from a cohort reported elsewhere
12
. 
Descriptive statistics were used to analyse demographic and wheelchair data. Clinical issues 
were categorised into major diagnosis contributing to the need for a wheelchair and whether 
it was inherited (autosomal dominant, recessive or X-linked). Other clinical data included 
comorbidities (conditions with no known or unlikely association with the index diagnosis) 
and additional clinical features (ACFs) which were features of the condition and/or features 
of disability likely to influence the wheelchair prescription.  
Rare diseases and powered mobility 
 
7 
 
Data were analysed using t tests for significant differences in age between those users with 
SS or TIS and without. 
This study was approved by the National Research Ethics Service. 
Results 
Fifty four EPIOC users, mean age 37.3 (sd 18.6, range 11-70) met the inclusion criteria. This 
was 10% of the original cohort
12
. There were 27 males with mean age of 36 (sd 17.7, range 
11-68) years and 27 females mean age 38.7 (sd 19.8, range 13-70) years.  The incidence or 
prevalence of their condition (where known) are given in Table 1 and their diagnoses and 
clinical features are given in Table 2.  
The majority of users have neurological conditions (n=31) of which 10 had Friedreich’s 
ataxia (five men, five women mean age 29.1, range 16-43, sd 11.0) and six had motor 
neurone disease (five men, one woman mean age 58, range 51-63.). A further three had 
neuromuscular conditions (central core disease, dystrophia myotonica and congenital 
myasthenia. Twenty users had disorders involving connective tissue and 42 users had 
inherited conditions, including two sisters both with infantile systemic hyalinosis (Table 2).  
Comorbidities and additional clinical features 
Sixteen users (30%) had no comorbidities or ACFs (Table 2). Nineteen users had between 
them 35 comorbidities and 31 users had a total of 45 ACFs (Table 2). Back pain was a 
common comorbidity (n=7) and one user had additional neck pain. Six users had three or 
more comorbidities.  
Hypertension was reported in 5 users. Scoliosis was a frequent ACF (n=8), as was 
problematic pain (n=10), often associated with other ACFs (Table 2). Four users had three or 
more ACFs. Eight users had needed orthopaedic surgery prior to EPIOC provision. 
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Wheelchair features.  
TIS was provided to 34 (63%) users and SS to 17 (31%). Six users had individually tailored 
seating systems. Carved foam seating was provided to three (achondroplasia, Friedreich’s 
ataxia and infantile systemic hyalinosis), Caps ll to a user with Krabbe’s disease, Matrix 
Seating to a user with osteogenesis imperfecta, and one user with Pelizaeus-Merzbacher 
disease was provided with a moulded seat insert. All other users needing SS were provided 
with appropriate standard cushions. TIS was provided to all eight users with scoliosis and SS 
to six with scoliosis. 
Those provided with SS were significantly younger than those who had standard equipment 
(p<0.004). There was no significant difference in age between those with TIS and those 
without.   
Complex controls 
Four users had between them complex controls (3), interfacing issues (2) and were tray 
mounted (2). A male aged 26 with osteogenesis imperfecta and comorbid asthma was 
provided with a tray mounted non-standard control system that needed to interface with other 
equipment. He required matrix seating but not TIS. A 16 year old female user with infantile 
systemic hyalinosis complicated by scoliosis and poor skin condition needed extra sensitive 
complex controls, SS and TIS. A 23 year old male with familial spastic paraplegia needed a 
tray mounted complex control and SS. A 20 year old female with Krabbe’s disease needed 
controls interfacing with a communication aid, SS and TIS.  
Ventilation 
Two users required wheelchair structures to support their oxygen cylinders. One was a 17 
year old male with Morquio’s disease complicated by lumbar and cervical spine fusions, hip 
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and knee surgery and residual severe pain. He was also prescribed SS and TIS. The other was 
a 59 year old male with motor neurone disease who also needed assessment for an 
environmental control unit. He was also provided with TIS but did not require SS.  
 
Discussion 
 
The 54 EPIOC users with RDs reported in this paper are a heterogeneous group, many with 
conditions rarely seen in clinical practice. Nonetheless they make up 10% of the whole 
EPIOC cohort
12
. This is the first study of EPIOC users with RDs that focuses on the 
implications for the wheelchair components of rehabilitation. This may reflect the emphasis 
placed historically on research into the genetics and diagnosis of these RDs and the 
previously low level of support for younger physically disabled individuals in the UK
39-40
. 
However, these individuals with RDs will seldom be seen in locality-based rehabilitation 
services. It is important that the proposed centres for the study of these conditions
41-42
 include 
rehabilitation expertise. 
For those with inherited conditions, the progress of each individual is unique depending on 
activity levels, growth rate and development. The challenge for EPIOC providers is to 
reconcile the physical disabilities with the individual’s need for function and participation 
whilst allowing for future disease progression and/or growth (for children). This is 
particularly important for those with small stature e.g. Morquio’s disease and for those with 
extreme vulnerability e.g. osteogenesis imperfecta. This is illustrated by the individual with 
Morquio’s disease (see results) who needed a complex prescription to accommodate the 
sequelae of his multiple orthopaedic surgery and need for oxygen. The SS (bespoke carved 
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foam) supported his joint derangements whilst the TIS helped to minimise his problematic 
pain.  He was provided with a 6-wheeled EPIOC providing a more stable base for a chair 
needing to accommodate an oxygen cylinder. However, for this individual, his residual 
abilities enabled him to control his chair using a standard joystick.  
Comorbidity and additional clinical features 
The results show that only 30% of this cohort had a single diagnosis, the remainder presented 
with complexities including a range of comorbidities and ACFs. It is often difficult to 
determine if clinical issues are due to the condition itself or the physical problems caused by 
disability and immobility.  Therefore while epilepsy is a noted comorbidity in familial spastic 
paraplegia, it is a known ACF of Pelizaeus-Merzbacher Disease. Epilepsy is not a 
contraindication to EPIOC use providing the user is daytime grand mal fit-free for at least 
one year, similar to the implications for drivers of motor vehicles
43
.  
It is thought that individuals with Friedreich’s ataxia are predisposed to developing 
diabetes
44
. One user with Friedreich’s ataxia had diabetes which was recognised as an ACF. 
There may be no immediate implications for EPIOC prescription in those with uncomplicated 
diabetes although it may eventually predispose users to pressure sores and leg ulcers. In 
contrast, one user with motor neurone disease also had diabetes complicated with a below-
knee amputation which was noted as a comorbidity. For those with severe immobility 
disability such as to require an EPIOC, dietary advice seems critical to prevent weight gain, 
obesity and minimise diabetic risk (as noted with multiple sclerosis
45
).   
Pain was a common clinical finding in this group with problematic pain affecting 10 users. 
Provision of a wheelchair in people with Morquio’s disease has been reported to alleviate 
pain and reduce fatigue although it is also indicated that health related QoL is reduced in 
wheelchair users
46
. It is likely that a similar situation applies to many EPIOC users and the 
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provision of TIS is one strategy for alleviating this pain
47-48
. In this group with RD, there is a 
preponderance, not seen in other studies, of powered wheelchair users with diseases affecting 
the musculoskeletal system, including the need for orthopaedic surgery with risks of post-
surgical pain, which may be alleviated by SS and TIS.  
Some ACFs noted are those that would be associated with prolonged sitting in a wheelchair 
including pressure sores, oedema and thromboembolism. 
Wheelchair features 
The eight users with clinically significant scoliosis present specific challenges for EPIOC 
providers. An appropriate balance must be sought between stabilising the spine and retaining 
flexibility in the wheelchair system to maximise residual upper limb and trunk function. This 
was resolved by providing TIS for flexibility and pain management to all eight users with 
scoliosis and SS to the six users needing extra support. Whilst surgery can ameliorate the 
progression of a scoliosis
49
, for many a scoliosis needs postural support by using SS to 
maintain posture and thus improve function
50
. 
Our largest group were those with Friedreich’s ataxia (n=10) and it is recognised that 
although some users with Friedreich’s ataxia become unable to control their wheelchair51, 
this study confirms that many remain able to do so without use of non-standard control 
systems or use of head or foot controls. This possibly reflects the fact that weakness is not the 
primary impairment for those with Friedreich’s ataxia52. Problematic pain was an issue for 
many Friedreich’s ataxia users and seven of the users had TIS which would help to manage 
pain
53-54
.  
Complex controls are needed when the user cannot manage a standard joystick. For those 
with substantial upper limb weakness and residual manual dexterity, the use of tray-mounted 
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controls provide support for the weak upper limb allowing movement of the hand and fingers 
to be utilized. This was the case for two users, one with osteogenesis imperfecta and the other 
with familial spastic paraplegia. Tray-mounted joysticks are usually centrally positioned and 
compete with space needed (e.g. for computers). Tray-mounted controls also facilitate 
interfacing controls for those who need additional electronic assistive technologies, as in the 
case of the user with osteogenesis imperfecta. For one user (with infantile systemic 
hyalinosis) with extremely limited manual dexterity, the option of extra sensitive controls 
enabled her to remain in control of her chair.  
Rehabilitation issues 
This paper contributes to the care pathways and clinical competencies that the UK 
Department of Health is striving to achieve
55
. Although rehabilitation is traditionally 
considered to be assisting recovery, rehabilitation professionals should also facilitate 
community living and participation for those with deteriorating conditions, which may be 
very hard to live with
51
. Often this will require assistive technologies including powered 
mobility being provided
56
 and is best effected by a comprehensive service delivered by a 
multiprofessional team
57
 including rehabilitation engineers skilled in assistive technology. 
The EPIOC service at Stanmore consisted of a multiprofessional team embracing a 
rehabilitation physician, therapists and engineers/clinical scientists able to provide a holistic 
approach to improving mobility and the facility to refer onwards where needed. Previous 
research has shown that users and their families are generally satisfied with the EPIOC 
service provided
10,58
, but some were concerned that they would not be assessed for their 
changing needs as they had deteriorating conditions
58
. This is particularly important for these 
RD, many of which will deteriorate over time.   
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The inclusion of the needs of caregivers and families in the rehabilitation assessment is 
particularly important in EPIOC provision for those with inherited RD as other family 
members may have developed an identical or similar disease. This was demonstrated by the 
two sisters with infantile systemic hyalinosis who needed a high level of family support and 
when provided with EPIOCs, required a larger home which the rehabilitation team 
recommended. 
Although it is reported that health related QoL is reduced and carer burden increased in 
wheelchair users with Morquio’s disease46 there is good evidence that provision of EPIOC 
improves quality of life
4
 and reduces caregiver burden, particularly as the need to push a 
manual wheelchair is reduced
59
.  
Although 75% of RD are in children
60
, some conditions may not have progressed to severe 
mobility disability until the individuals have reached adulthood. In our cohort, two such 
examples are EPIOC users with Sandhoff’s disease and Pelizaeus-Merzbacher disease who 
were aged 52 and 36 respectively. What is unclear from data we were able to obtain was 
information about their rehabilitation pathway that led them to referral for an EPIOC (noting 
that those in the United Kingdom could self-refer to a wheelchair service). However, recent 
European recommendations for the management of mucopolysaccharidosis  type 11 focuses 
on multidisciplinary team support, including physiotherapy to maintain ambulation with 
assistive devices if needed
61
. The lack of any mention of assistive technology in that review is 
not atypical. It reflects the lack of understanding of powered mobility as a major therapeutic 
tool, enhancing mood through greater independence and social interaction, reducing pain, 
assisting swallowing and ventilation on occasions, and reducing caregiver burden. 
Limitations of study 
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It is recognised that the ACFs of these rare diseases may be incomplete or imprecise due to 
the paucity of literature reporting long term follow-up of these individuals. Consequently our 
categorisation was led by clinical judgement and the available history of each user. Because 
data were extracted from records that were designed for clinical use, only data relevant to 
EPIOC prescription were recorded. The data represents the clinical picture at a particular 
time, which may limit generalisability to other powered wheelchair populations. Service 
reorganisation prevented further follow-up of these users. 
Our study did not include those who had purchased wheelchairs privately or through 
charitable funding (more often available for children), nor scooters. Many of these users 
would have maintained balance ability and so those without severe deformity might have 
purchased scooters.  
Conclusions 
Our EPIOC users with rare diseases reached the wheelchair service in their adult or teenaged 
years despite having an inherited and incurable progressive health condition. Their complex 
and diverse clinical problems presented unique challenges to the multi-professional 
wheelchair team to maintain successful community living. Early intervention is 
recommended and should take a health promotion approach to the long-term management of 
rare diseases through the provision of EPIOCs and specialised seating. This is preferable to 
addressing problems of severe disability and clinical complications once they have become 
established and when complex remedial, rehabilitation and medical interventions are 
required. 
The recommended national strategies for RD
55,62-63
 need to include rehabilitation in all its 
complexity and the potential of assistive technology to improve the wellbeing of those with 
RD and their families.  
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Table 1.Diagnosis, incidence/ prevalence and effects of rare diseases in 54 Electric powered indoor/outdoor wheelchair users. 
 
 
Condition Also called  Incidence/prevalence* Effects 
 
  
 
 
Achondroplasia Achondroplastic dwarfism  1: 26,000 - 34,60815 Mutation of fibroblast growth factor receptor 
Arthrogryposis ARC Syndrome  1: 3,00016 Soft tissue, joint & skeletal deformity 
Ataxia telangectasia   0.4:100,000 *  17 Progressive difficulty with coordinating 
movements (ataxia) 
Central core disease Shy-Magee syndrome  < 6: 100,000 live births18;19 Congenital myopathy 
Cerebellar syndromes   0.3 – 2:100,000 for spinocerebellar 20  Dysfunction of balance and movement 
Congenital myasthenia Erb-Goldflam syndrome  Unknown - very rare21 Neuromuscular weakness 
Dejerine-Sottas disease HMSN TYPE 111  < 1: 1,000,00022 Polyneuropathy 
Dystrophia epidermolysis 
bullosa 
  12-19 / million births23;24 Skin erosion and blistering 
Dystrophia myotonica   10.6: 100,000* 19 progressive muscle wasting and weakness 
Familial spastic paraplegia Hereditary spastic paraplegia 
Strümpell-Lorrain syndrome 
 1.5 – 2.7:100,00025 progressive and severe lower extremity 
weakness and spasticity. 
Fibrodysplasia ossificans 
progressiva 
Myositis Ossificans  1:2,000,000 *26 Ossification of connective tissue 
Friedreich’s ataxia 
  
0.15:100,000 * 17 
Dysfunction of balance, movement and 
proprioception 
Guillain-Barre Syndrome   0.34 and 1.34/100,00027 Acute progressive muscle weakness 
Infantile systemic hyalinosis Hyaline fibromatosis 
syndrome 
 < 1: 1,000,000 (52 reported cases world-wide)28 Hyalin deposits in tissues 
Keratoderma 
 
Focal palmoplantar 
keratoderma 
 Unclear Severe blisters and calluses on the feet 
Krabbe's disease Galactocerebrosidase 
deficiency; globoid-cell 
leukodystrophy 
 1:100,000*29 Cerebral demyelination 
Leukodystrophy: 
undiagnosed 
  
< 1 :7663 births30 
Progressive demyelination resulting in 
widespread motor and sensory dysfunction 
McCune-Albright syndrome Polyostotic fibrous dysplasia  1: 100,000 - 1,000,000 people worldwide31 Fibrous dysplasia of bone, progressive scoliosis, 
short stature 
Morquio's disease Mucopolysaccharidosis  1: 100,000 births32 Enzyme deficiency 
Motor neurone disease amyotrophic lateral sclerosis  0.6 – 2.4:100,00033 Degeneration of motor neurones resulting in 
muscle weakness and wasting 
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Multisystem atrophy   0.6 cases per 100.00034 Combination of parkinsonian, autonomic, 
cerebellar or pyramidal symptoms and signs 
Osteogenesis imperfecta Brittle bone disease  1:20,000 births35 Connective tissue 
Pelizaeus-Merzbacher 
Disease 
Cockayne-Pelizaeus-
Merzbacher Disease; PMD 
 <1:100,00030 Growth of the myelin sheath 
Progressive supranuclear 
palsy 
  1 per 100,00036 Severe parkinsonism 
Sandhoff's  disease Sandhoff-Jatzkewitz-Pilz 
disease; Total 
hexosaminidase deficiency 
 1:422,00037 Neuronal destruction in brain and spinal cord 
Spondylocostal dysplasia Jarcho-Levin syndrome; 
spondylocostal dysostosis; 
 
 0.25 / 10,000 births16 Severe malformations of the vertebral column 
and ribs 
Winchester syndrome 
 
Winchester Disease 
 
<1 :1 000,000 (10 patients reported up to 2001)*38 
Short stature, generalized osteolysis and 
progressive painful arthropathy 
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Table 2. Clinical and demographic features or 54 EPIOC users and their wheelchair provision 
 
 
Condition 
No 
(male) Comorbidities (cases) Additional clinical features (cases) 
Main 
diagnosis 
only 
SS TIS Mean 
Age 
(range) 
Achondroplasia†^ 2 (0) SCI (1): OA, DB, 
hypertension (1) 
Pressure sore (1) 0 1 0 62.5 
(60-65) 
Arthrogryposis†^ 
 
 
4 (1) 
 
 
Skin rash (1): OA + BP 
and NP (1) 
 
Painful post hip replacement (1): scoliosis + 
contractures (1): OA hips (1) 
 
1 0 4 
31.5 
(15-49) 
Ataxia telangectasia^ 1 (1)   1 0 1 44 
Central core disease^ 1 (1)   1 0 1 19 
Cerebellar syndromes (2 
cerebellar ataxia) (2 spino-
cerebellar ataxia^)  
4 (0)  Problematic spasticity (1) 3 0 3 49.8 
(28-61) 
Congenital myasthenia^ 1 (1)   1 0 1 11 
Dejerine-Sottas disease^ 1 (1)  Deep vein thrombosis and pulmonary embolism 
(1) 
0 0 0 43 
Dystrophia epidermolysis 
bullosa†^ 
1 (1)  Abdominal pain? related to skin (1) 0 0 0 15 
Dystrophia myotonica^ 1 (1) Problematic painful 
BP/coccidynia (1) 
Swallowing difficulty (1) 0 0 0 54 
Familial spastic paraplegia^ 2 (2) Epilepsy + hypertension + 
BP + ankle pain (1) 
 1 1 0 45.5  
(23-68) 
Fibrodysplasia ossificans 
progressiva†^ 1 (1) BP (1) 
Scoliosis with pelvic obliquity + problematic pain 
(1) 
0 1 1 
23 
Friedreich’s ataxia^ 10 (5) Psoriasis (1): BP + 
hypertension (1): BP (1): 
colonic + nasal polyps + 
peptic ulcer + BP (1) 
Scoliosis (2): DB (1): choking/swallowing 
difficulties (1): aortic valve disease (1): obesity + 
oedema + problematic pain (1): oedema (1): 
scoliosis + problematic pain + choking (1) : 
hypertrophic cardiomyopathy + pressure sore 
(1): problematic pain + oedema (1) 
1 4 7 29.1 
(16-43) 
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Guillain-Barre syndrome 1 (0) OA knees and hands with 
failed surgery +asthma + 
hypertension (1) 
 0 0 1 68 
 
Infantile systemic hyalinosis†^ 
 
2 (0) 
sisters 
  
Scoliosis (1): scoliosis + fragile skin (1) 
 
0 
 
2 
 
2 
 
15 
(14-16) 
Keratoderma†^ 1 (1) Hypermobility (1) Severe pain (1) 0 0 0 23 
Krabbe's disease^ 1 (0)  Communication impairment (1) 0 1 1 20 
Leukodystrophy: undiagnosed^ 1 (0)   1 1 0 13 
McCune-Albright syndrome† 
1 (0)  Multiple fractures +precocious puberty + 
Cushing’s syndrome (1) 
0 1 1 15 
Morquio's disease†^ 2 (1) Asthma (1) 
Severe pain following spinal fusions + ventilatory 
failure (1): Previous two spinal fusions (1) 
0 1 2 23  
(17-29) 
Motor neurone disease 
 
6(5) DB + below knee 
amputation (1) 
Ventilatory failure (1) 4 0 4* 58 
(51-63) 
Multisystem atrophy 1 (0)  Postural hypotension (1) 0 0 0 58 
Osteogenesis imperfecta†^ 4 (2) Asthma (2) Painful scoliosis + impaired hearing (1) 1 3 3 35 
(17-60) 
Pelizaeus-Merzbacher disease^ 1 (1)  Epilepsy (1) 0 1 0 36 
Progressive supranuclear palsy 1 (0) Hypertension + irritable 
bowel syndrome + 
diverticular disease (1) 
 0 0 0 70 
Sandhoff's disease^ 1 (1) Shoulder pain 
(wheelchair user’s) (1) 
 0 0 1 52 
Spondylocostal dysplasia†^ 1 (1)   1 0 0 19 
Winchester syndrome†^ 1 (0)  Polyarthralgia + NP + oedema (1) 0 0 1 34 
Total 
54 
(27) 
 35 (19)  45 (31) 16 17 34* 37.3 
(11-70) 
 
Key: † Disorders involving connective tissues.^ Autosomal dominant, recessive or X-linked inheritance. * TIS unknown for one user. DB: Diabetes, OA: 
osteoarthritis, SCI: spinal  cord injury, BP: back pain, NP: neck pain 
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